Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASRT Assertio	$0.82 +0.7%	$0.69	$0.51 ▼ $1.38	$78.18M	0.28	295,547 shs	216,099 shs
CING Cingulate	$4.13 +12.2%	$4.61	$3.02 ▼ $20.83	$19.37M	-0.74	163,037 shs	368,375 shs
CNTX Context Therapeutics	$0.74 +5.2%	$0.70	$0.49 ▼ $2.70	$62.79M	1.89	167,588 shs	94,477 shs
UNCY Unicycive Therapeutics	$4.63 +5.0%	$5.28	$2.75 ▼ $11.00	$55.75M	1.88	373,239 shs	530,441 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASRT Assertio	+0.74%	+13.01%	+23.93%	+22.90%	-23.52%
CING Cingulate	+12.23%	-1.90%	-8.63%	+8.12%	+123.24%
CNTX Context Therapeutics	+5.19%	+5.34%	+0.14%	+3.44%	-71.68%
UNCY Unicycive Therapeutics	+4.99%	+14.04%	+0.22%	-22.30%	+46.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASRT Assertio	2.4943 of 5 stars	3.5	2.0	2.1	0.8	1.3
CING Cingulate	2.2621 of 5 stars	3.5	3.0	1.6	0.8	0.6
CNTX Context Therapeutics	3.4802 of 5 stars	3.6	4.0	2.8	1.7	1.3
UNCY Unicycive Therapeutics	2.6166 of 5 stars	3.7	2.0	2.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASRT Assertio	3.00	Buy	$2.38	190.24% Upside
CING Cingulate	3.00	Buy	$26.00	529.54% Upside
CNTX Context Therapeutics	3.17	Buy	$5.25	613.02% Upside
UNCY Unicycive Therapeutics	3.33	Buy	$60.00	1,195.90% Upside

Current Analyst Ratings Breakdown

Latest CING, ASRT, UNCY, and CNTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	ASRT Assertio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.50 ➝ $3.00
8/8/2025	CING Cingulate	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/7/2025	CNTX Context Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
8/7/2025	CNTX Context Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/26/2025	CNTX Context Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$4.50 ➝ $4.00
5/27/2025	CING Cingulate	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$60.00 ➝ $61.00
5/27/2025	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$90.00
5/19/2025	CING Cingulate	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$12.00 ➝ $11.00
5/19/2025	ASRT Assertio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.50 ➝ $3.50

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASRT Assertio	$124.96M	0.63	$0.05 per share	16.55	$0.97 per share	0.84
CING Cingulate	N/A	N/A	N/A	N/A	$2.32 per share	N/A
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	$0.92 per share	N/A
UNCY Unicycive Therapeutics	$680K	86.06	N/A	N/A	$0.72 per share	6.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASRT Assertio	-$21.58M	-$0.45	N/A	27.28	N/A	-36.97%	-38.19%	-15.45%	N/A
CING Cingulate	-$15.55M	-$8.48	N/A	N/A	N/A	N/A	-229.78%	-142.28%	N/A
CNTX Context Therapeutics	-$26.73M	-$0.36	N/A	N/A	N/A	N/A	-38.80%	-37.53%	N/A
UNCY Unicycive Therapeutics	-$36.73M	-$5.10	N/A	N/A	N/A	N/A	-277.30%	-61.53%	N/A

Latest CING, ASRT, UNCY, and CNTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	UNCY Unicycive Therapeutics	-$0.70	-$0.52	+$0.18	-$0.52	N/A	N/A
8/11/2025	Q2 2025	ASRT Assertio	-$0.10	-$0.17	-$0.07	-$0.17	$27.86 million	$29.22 million
8/6/2025	Q2 2025	CNTX Context Therapeutics	-$0.06	-$0.09	-$0.03	-$0.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASRT Assertio	N/A	N/A	N/A	N/A	N/A
CING Cingulate	N/A	N/A	N/A	N/A	N/A
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASRT Assertio	0.42	1.59	1.35
CING Cingulate	0.16	1.87	1.87
CNTX Context Therapeutics	N/A	19.09	19.09
UNCY Unicycive Therapeutics	N/A	1.64	1.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASRT Assertio	48.96%
CING Cingulate	41.31%
CNTX Context Therapeutics	14.03%
UNCY Unicycive Therapeutics	40.42%

Insider Ownership

Company	Insider Ownership
ASRT Assertio	4.00%
CING Cingulate	5.27%
CNTX Context Therapeutics	2.80%
UNCY Unicycive Therapeutics	10.71%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASRT Assertio	20	96.24 million	92.39 million	Optionable
CING Cingulate	20	5.26 million	4.99 million	Not Optionable
CNTX Context Therapeutics	7	89.70 million	87.19 million	Not Optionable
UNCY Unicycive Therapeutics	9	12.64 million	11.29 million	Not Optionable

CING, ASRT, UNCY, and CNTX Headlines

Recent News About These Companies

Unicycive Therapeutics reports Q2 EPS (52c), consensus (70c)

4 hours ago | msn.com

Unicycive Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

August 14 at 4:14 PM | gurufocus.com

Unicycive Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

August 14 at 3:55 PM | globenewswire.com

Unicycive Therapeutics requests Type A meeting with FDA to discuss CRL

August 14 at 2:05 PM | msn.com

Unicycive Therapeutics expects cash to fund operations into 2H of 2026

August 14 at 2:05 PM | msn.com

Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

August 14 at 7:00 AM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

August 13 at 12:33 PM | globenewswire.com

Unicycive Therapeutics (UNCY) Projected to Post Quarterly Earnings on Wednesday

August 12 at 8:43 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

August 11, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

August 9, 2025 | globenewswire.com

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Holdings Lifted by Vivo Capital LLC

August 9, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

August 6, 2025 | prnewswire.com

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Up 1,211.2% in July

August 3, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

July 31, 2025 | prnewswire.com

Unicycive Therapeutics Inc Ordinary Shares UNCY - Morningstar

July 30, 2025 | morningstar.comM

Unicycive Therapeutics (NASDAQ:UNCY) Trading Down 6.2% - Here's What Happened

July 30, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

July 28, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

July 27, 2025 | prnewswire.com

Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology

July 24, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

July 23, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

July 22, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CING, ASRT, UNCY, and CNTX Company Descriptions

Assertio NASDAQ:ASRT

$0.82 +0.01 (+0.74%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$0.82 +0.00 (+0.45%)

As of 08/14/2025 07:37 PM Eastern

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Cingulate NASDAQ:CING

$4.13 +0.45 (+12.23%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$4.20 +0.07 (+1.57%)

As of 08/14/2025 07:57 PM Eastern

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Context Therapeutics NASDAQ:CNTX

$0.74 +0.04 (+5.19%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$0.75 +0.01 (+1.86%)

As of 08/14/2025 07:58 PM Eastern

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Unicycive Therapeutics NASDAQ:UNCY

$4.63 +0.22 (+4.99%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$4.58 -0.04 (-0.97%)

As of 08/14/2025 07:50 PM Eastern

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time